Background: Ovarian sex cord-stromal tumours (SCST) are relatively uncommon neoplasms that account for approximately 5-7% of all primary ovarian tumours. The aim was to report experience with sex cord stromal tumours (SCST) of ovary in a low and middle income country.
Methods: Clinical records of 56 patients with histopathologically-established SCST of ovary admitted to a tertiary care cancer hospital in Pakistan between April 1995 and December 2011 were reviewed.
Results: Median age at presentation was 41 years (Range 4-77). Forty one (73%) patients were premenopausal and 15 (26.8%) were postmenopausal. The most common presenting complaint was abdominal pain (28.1%). Thirty seven patients (66%) had stage-I, 2 had stage II and II each, and 15 (26.8%) had stage IV disease. Five years survival in patients with early stage (stages I & II) was 91% while in those in the late stage (II & IV) was 84% (p=0.79). Histopathologically, 49 patients (85.7%) had Granulosa cell tumour, and 7 (12.5%) had Sertoli Lyedig cell tumour. CA-125 was high only in 8 patients (14.3%). Adjuvant chemotherapy was give in 16 (28.6%). Thirty six (64%) were disease free at last follow up, 10 (18%) succumbed to disease and 10 (18%) were alive with disease. On univariate and multivariate analyses, late stage at presentation was the sole factor significantly associated with mortality.
Conclusion: Ovarian sex cord-stromal tumours of ovary are relatively uncommon malignancies with good prognosis if diagnosed early and treated adequately. Survival in our study was comparable to those reported elsewhere. Among various factors, late stage of tumour at presentation was found to be the only factor significantly associated with mortality.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.
Arch Dermatol Res
January 2025
Division of Gastroenterology and Hepatology, 200 1st Street SW, Rochester, MN, 55905, USA.
Background: Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.
View Article and Find Full Text PDFDisparities in utilization of novel cancer therapies in advanced stage III and IV melanoma and variance in outcomes.
Immunotherapy
January 2025
Department of Surgery, Division of Surgical Oncology, Roger Williams Medical Center, Providence, RI, USA.
Introduction: Significant gains in advanced melanoma have been made through immunotherapy trials. Factors influencing equitable access and survival impact of these novel therapies are not well-defined.
Method: Retrospective analysis using National Cancer Database of patients with advanced stage III and IV melanoma from 2004 to 2021.
Multiplexed transcriptomic analyzes of the plant embryonic hourglass.
Nat Commun
January 2025
School of Integrative Plant Science, Plant Biology Section, Cornell University, Ithaca, NY, USA.
Zoologists have adduced morphological convergence among embryonic stages of closely related taxa, which has been called the phylotypic stage of embryogenesis. Transcriptomic analyzes reveal an hourglass pattern of gene expression during plant and animal embryogenesis, characterized by the accumulation of evolutionarily older and conserved transcripts during mid-embryogenesis, whereas younger less-conserved transcripts predominate at earlier and later embryonic stages. In contrast, comparisons of embryonic gene expression among different animal phyla describe an inverse hourglass pattern, where expression is correlated during early and late stages but not during mid-embryo development.
View Article and Find Full Text PDFEmergence of Neuroendocrine Tumors in Patients Treated with Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Eur Urol Oncol
January 2025
Cancer Heterogeneity Plasticity and Resistance to Therapies (CANTHER) Research Group, CHU Lille, Institut Pasteur de Lille, and University of Lille, Lille, France; Department of Urology, Hospital Claude Huriez, CHU Lille, Lille, France. Electronic address:
Background And Objective: It has been shown that androgen receptor pathway inhibitor (ARPIs) treatment for metastatic castration-resistant prostate cancer (mCRPC) improves overall survival rates, but ARPIs appear to be associated with a higher frequency of treatment-related neuroendocrine prostate cancer (t-NEPC). Our aim was to quantify the proportion of prostate adenocarcinoma cases that transition to t-NEPC following ARPI therapy.
Methods: We conducted a comprehensive search of the literature on t-NEPC using databases including MEDLINE and Scopus.
Dissociating the Roles of Alpha Oscillation Sub-Bands in Visual Working Memory.
Neuroimage
January 2025
Institute of Brain and Psychological Sciences, Sichuan Normal University, 610066 Sichuan, China; Brain and Cognitive Neuroscience Research Center, Liaoning Normal University, 116029 Liaoning, China. Electronic address:
Alpha oscillations play a critical role in visual working memory (VWM), but the specific contributions of lower and upper alpha sub-bands remain unclear. To address this, we employed a whole-field change detection paradigm to investigate how alpha power modulation and decoding accuracy differ between these sub-bands in response to varying set sizes and spatial extents of memory arrays. Our results revealed that lower alpha (8-9 Hz) exhibits widespread event-related desynchronization (ERD) during the early maintenance phase, which increases with set size and reflects attentional allocation to individual memory items.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!